ISPC · iSpecimen Inc.
$2.16
+0.24 (+12.50%)
At close · Aug 6
Going-concern doubt
— flagged May 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year from the date these unaudited condensed financial statements are issued. Management’s plan to mitigate the conditions that raise substantial doubt includes generating additional revenues, deferring certain projects and capital expenditures and eliminating certain future operating expenses for the Company to continue as a going concern. However, there can be no assurance that the Company will be successful in completing any of these options. As a result, management’s plans cannot be considered probable and thus do not alleviate substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 18, 2026
Market Cap
$2.76M
Shares
1.44M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.92
Open$2.14
Day$1.91–2.22
52W$1.77–127.20
Avg vol 30d90K
Short int185K · 12.8% float · 1.2d
Short vol48%
Last earningsAug 6, 2024
DataJun 2021–Aug 2026
Filing10-Q · May 18
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 18, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−82%
below
Price vs 50-day avg
−25%
below
RSI (14)
38
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
−85%
trailing
YTD return
−82%
this year
Relative strength
−96%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
4 of 12 funds reported for Jun 30 · net +8.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.84% of float · ▲ +17.8% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Squeeze score
56
elevated · 0–100
Fundamentals
Revenue growth
−79%
Y/Y
EPS growth
+87%
Y/Y
Free cash flow
$-4.2M
Balance sheet
$3.5M
net cash
Quant / Vol
risk profile
Volatility
213%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
10.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−82%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
38
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $3 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
4 of 12 funds reported for Jun 30 · net +8.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.84% of float · ▲ +17.8% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $2
Now $2 · 0%
52-wk high $127
vs 200-day avg -82%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ISPC
this stock
iSpecimen Inc.
|
$2.76M | -81.5% | -79.2% | — | 12.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$213.65B | -0.1% | +0.4% | 31.1 | 1.4% |
|
DHR
Danaher Corp /De/
|
$140.36B | -12.4% | +8.5% | 35.4 | 1.4% |
|
IDXX
Idexx Laboratories Inc /De
|
$46.07B | -13.6% | +10.4% | 41.1 | 2.7% |
|
A
Agilent Technologies, Inc.
|
$39.81B | +4.3% | +6.4% | 28.3 | 2.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ISPC | +1.1% | -16.2% | -84.5% | +1.6% | -81.5% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -4.5% | -19.4% | -95.8% | -1.5% | -94.4% |